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Abstract
Malaria is transmitted by Plasmodium-infected anopheles mosquitoes. Widespread resistance of mosquitoes to insecticides
and resistance of parasites to drugs highlight the urgent need for malaria vaccines. The most advanced malaria vaccines
target sporozoites, the infective form of the parasite. A major target of the antibody response to sporozoites are the repeat
epitopes of the circumsporozoite (CS) protein, which span almost one half of the protein. Antibodies to these repeats can
neutralize sporozoite infectivity. Generation of protective antibody responses to the CS protein (anti-CS Ab) requires help by
CD4 T cells. A CD4 T cell epitope from the CS protein designated T* was previously identified by screening T cells from
volunteers immunized with irradiated P. falciparum sporozoites. The T* sequence spans twenty amino acids that contains
multiple T cell epitopes restricted by various HLA alleles. Subunit malaria vaccines including T* are highly immunogenic in
rodents, non-human primates and humans. In this study we characterized a highly conserved HLA-DRb1*04:01 (DR4)
restricted T cell epitope (QNT-5) located at the C-terminus of T*. We found that a peptide containing QNT-5 was able to elicit
long-term anti-CS Ab responses and prime CD4 T cells in HLA-DR4 transgenic mice despite forming relatively unstable MHC-
peptide complexes highly susceptible to HLA-DM editing. We attempted to improve the immunogenicity of QNT-5 by
replacing the P1 anchor position with an optimal tyrosine residue. The modified peptide QNT-Y formed stable MHC-peptide
complexes highly resistant to HLA-DM editing. Contrary to expectations, a linear peptide containing QNT-Y elicited almost
10-fold lower long-term antibody and IFN-c responses compared to the linear peptide containing the wild type QNT-5
sequence. Some possibilities regarding why QNT-5 is more effective than QNT-Y in inducing long-term T cell and anti-CS Ab
when used as vaccine are discussed.
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Introduction
Despite a significant reduction in the incidence and number
deaths due to malaria, this disease claimed over 600,000 human
lives in 2011 [1]. The widespread resistance of mosquitoes to
insecticides and of malaria parasites to drugs greatly encourages
the development of a malaria vaccine as a long-term solution.
Vertebrates are infected when malaria-infected mosquitoes inoc-
ulate sporozoites during a blood meal. Studies in the last century
with irradiated sporozoites [2–6] and more recently with
cryopreserved radiation-attenuated purified P. falciparum sporozo-
ites [7] demonstrate that solid and reproducible protection to
malaria challenge can be achieved by immunization with
sporozoites. In rodents has been shown that a major target of
the protective immune response to sporozoites is the circumspor-
ozoite (CS) protein [8] that uniformly cover the surface of the
sporozoite. Studies in rodents and more recently in humans
immunized with RTS,S a leading malaria vaccine based on the CS
protein [9], or irradiated sporozoites have shown that anti-CS
antibodies are higher in protected individuals than in those non-
protected [7,10]. In malaria mouse model protection to sporozoite
challenge was achieved by passive transfer of antibodies to the CS
protein [11] and in a simian host by incubation of anti-CS
antibodies with sporozoites before injection in susceptible hosts
[12,13]. A major target of the anti-CS neutralizing antibodies are
continuous repetitive units [13–16] located in the central region of
the protein and that are characteristic of the malaria parasite
species. In the human malaria parasite Plasmodium falciparum the
repetitive units are represented by 6 copies of the minor (NVDP)
repeats interspersed within up to 40 major (NANP) repeats.
Analysis of T cell responses of individuals immunized with a
synthetic vaccine [17] and of naturally exposed individuals [18]
suggest that P. falciparum repeats are poor immunogens and
antibody responses are only elicited in a restricted number of
individuals of defined genotypes [19].
Responses in CD4 T cells are elicited upon engagement of T
cell receptors on these cells with class II MHC (MHCII) molecules
on the surface of professional antigen presenting cells (APCs).
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Peptides bind to MHCII molecules by a conserved network of
hydrogen bonds between the peptide backbone and conserved
MHCII side chains and by interactions between pockets in the
MHCII binding groove and peptide side chains [20]. During
assembly of MHCII-peptide complexes the peptide editor HLA-
DM surveys the binding of epitopes by releasing weakly-associated
peptides. This editing represents one important step in immuno-
dominance determination. Studies on the immunogenicity of CD4
T cells for foreign viral antigens [21], model antigens [22], and
antigens involved in auto-immunity [23], suggest an important
role of HLA-DM in the selection of MHCII-peptide complexes
with high kinetic stability. Sant and colleagues reviewed the
relationship between immunodominance, HLA-DM editing, and
kinetic stability of MHCII-peptide complexes and suggested that
for CD4 T cell responses immunodominance is primarily due to
an intrinsic property of MHC-peptide complex stability [24]. Most
studies have assessed the relationship between MHCII-peptide
complex stability and CD4 immunogenicity using T cell read outs
such as proliferation or IL-2 and IFN-c production [21,22,24,25].
At present there is little information regarding the impact that
MHC-peptide complex stability has on the capacity of CD4 T cell
epitopes to provide help for production of antibodies by B cells.
In addition to antibodies, protection against P. falciparum
sporozoites has been correlated with the presence of CD4 T
helper cells producing IFN-c in vaccinated volunteers [26] and
naturally infected individuals living in Africa [27]. A good CD4 T
helper epitope must be ‘‘universal’’ (recognized by CD4 T
lymphocytes in MHC haplotypes widely distributed in the
population). The search of universal epitopes in the CS protein
has been successful; Sinigaglia identified a conserved region
(CS.T3) recognized by different MHCII molecules in both mouse
and man [28]; Doolan identified three promiscuous T cell epitopes
(CSP-2, CSP-53 and CSP-375) recognized by HLA-DR molecules
representative of the most common MHCII DR molecules
worldwide [29] and Moreno and colleagues described an epitope
named T* (CS 326–345) presented by multiple MHCII DR
molecules [30]. The fine mapping of human CD4 T cell responses
within universal epitopes and other regions of P. falciparum CS
protein has identified five CD4 T helper cell epitopes designated as
T1, Th2R, Th3R, CS.T3 and T* [18,30–33]. The immunoge-
nicity of Th2R, Th3R, CS.T3 and T* has been demonstrated in
clinical trials by Reece and colleagues who demonstrated that
response to CS.T3 is strongly associated with protection of human
individuals living in Africa and by Wang [34] and Schwenk [35]
that evidenced prevalent responses of CD4 T cells against Th2R,
T* and CS.T3 in individuals immunized with the RTS,S malaria
vaccine.
Analysis of the CD4 T cell response to the T* sequence has
demonstrated that T* contains multiple overlapping epitopes that
induce CD4 T cell responses in humans and mice of diverse MHC
haplotypes [30,36,37]. CD4 T cell clones specific for regions
contained in T* have been generated from volunteers immunized
with irradiated sporozoites [30]. In a clinical trial, Nardin and
colleagues demonstrated antigen specificity and function of T*-
specific CD4 T cell clones isolated from volunteers immunized
with a fully synthetic vaccine (T1BT*)4-Pam3Cys comparable to
those of clones derived from volunteers immunized with irradiated
P. falciparum sporozoites [30,36,38].
T* harbors two HLA-DRb1*04:01 (DR4) CD4 T cell epitopes
as predicted originally by Parra-Lo´pez [39] one highly polymor-
phic epitope at the N-terminus known as T*-1 that overlaps with a
DR4 T cell epitope originally described by Moreno et al., [30] and
one conserved epitope near C-terminus known as QNT-5 [39]. In
this work, we performed a detailed characterization of the
interaction of HLA-DR4 with T*-1 and QNT-5 peptides and
studied the immune response to a linear peptide containing both
epitopes in HLA-DR4 individuals in order to evaluate their value
as potential T helper epitopes for antibody production. We found
that the QNT-5 peptide forms a kinetically unstable complex with
DR4. By changing the pocket 1 residue in QNT-5 from leucine to
tyrosine a highly stable analogous epitope (QNT-Y) resistant to
DM editing was created. QNT-Y elicited QNT-5 crossreactive T
cells in DR4 transgenic mice and in vitro primed naı¨ve CD4 T cells
from human DR4 individuals. Although QNT-Y improved short
term cellular as well as antibody responses in HLA-DR4
transgenic mice, in the long term QNT-5 was more effective in
inducing these responses. These findings show that factors other
than kinetic stability determine the T cell immunogenicity of
QNT-5. Thus, MHC-peptide complex stability may not be a strict
requirement for the generation of memory T cells that foster long-
term antibody responses.
Materials and Methods
Human samples
Blood samples (400 mL) were taken and processed from healthy
volunteers at the blood bank Hemocentro Distrital, Bogota´-
Colombia (http://www.bogota.gov.co/tag/hemocentro-distrital),
after the informed consent form was signed. This study was
approved by Ethics committee of Universidad Nacional de
Colombia Medical School – (protocol No. CE-159, 14 August
2009 Act. 12). Buffy-coats from DR4 volunteers handed to us by
the blood bank were used to isolate PBMCs by density-gradient
centrifugation over Histopaque (GE Healthcare). PBMCs were
cryopreserved in 50% RPMI-1640 +40% FBS +10% DMSO in
liquid nitrogen.
Peptides
Synthetic peptides included in this study HA306–318
PKYVKQNTLKLAT; T*326–345 EYLNKIQNSLSTEWSPCSVT
(NF-54 variant); T*-1327–338 YLNKIQNSLSTE; QNT-5332–345
QNSLSTEWSPCSVT; three QNT-5 analogues at position L335:
QNT-Y (L335Y), QNT-F (L335F) and QNT-W (L335W); fourteen
alanine analogues of the QNT-5 sequence (QN-Q332 to QN-T345);
four QNT-5 truncated peptides (QN-334-345; QN-332-343; QN-
335-343; QN-336-343); T1B a linear peptide containing the epitope
T1 (DPNANPNVDPNANPNV) [31] and three copies of the B cell
epitope (repeat NANP from the CS protein) [31]; the linear peptide
T1BT* containing the epitope T1B sequence followed by the T*
epitope (DPNANPNVDPNANPNV(NANP)3EYLNKIQNSL-
STEWSPCSVT) and the peptide construct T1BT*-Y that contains
the T1B sequence followed for the T* analogue L335Y named
herein after peptide QNT-Y (DPNANPNVDPNANPNV(NAN-
P)3EYLNKIQNSYSTEWSPCSVT) were synthesized by 21
st Cen-
tury Biochemicals (Marlboro, MA), by the multiple-solid-phase
technique, using tert-butoxycarbonyl (Boc) strategy as previously
described [40]. QNT-5 alanine analogues and truncated peptides
were synthesized acethylated/amide at the N- and C- terminus
respectively. All peptides were purified by reverse-phase High
Performance Liquid Chromatography (HPLC) on a C18 LiChro-
spher column (Merck, Germany). The quality of the products was
assessed by analytical HPLC and mass spectrometry (MALDI-
TOF). The biotin-labeled peptides HA306–318; T*326–345; T*-1327–
338, QNT-5332–345 and its analogue QNT-Y, were N-terminally
labeled using biotin derivative sulfo-NHS-LC-Biotin (Pierce Chem-
ical, Rockford, Illinois). The peptide (NANP)6 was kindly provided
by Dr. A. Moreno (Emory University).
Epitope Immunogenicity and MHC-Peptide Stability
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Soluble Recombinant DR4
Expression of soluble DR4 was performed using stable
transfectants of Drosophila S2 Schenider cells, as described
previously for DR1 [41]. Stable transfected cell lines were
established by selection under 1.0 mg/L geneticin (Invitrogen
Life technologies – California, USA) and grown in SF900 medium
(Invitrogen Life technologies – California, USA) supplemented
with 100 U/mL penicillin, 100 mg/mL streptomycin (Invitrogen
Life technologies – California, USA), 250 mg/L amphotericin B
and 2 mM L-glutamine (Invitrogen Life technologies – California,
USA), at 22–24uC. Cell cultures were induced at a density of 5–
106106 per mL by the addition of 0.5 mM CuSO4 and culture
supernatant was collected 4–6 days later by centrifugation at
4000xg. Supernatant was concentrated 10-fold in a 10,000
molecular weight cut-off spiral filtration device (Millipore,
Massachusetts, USA). DR4 was purified by immunoaffinity with
LB3.1-conjugated protein A column, as described [42]. The final
yield of DR4 was in the range of 0.2–0.5 mg/L of cultured cells.
Recombinant HLA-DM-molecule and DR4/peptide
tetramers
Recombinant HLA-DM was produced by expression in stably
transfected S2-cells [43] essentially as described above for HLA-
DR4 except that M2 (anti-flag tag) rather than LB3.1 was used for
immunoaffinity. Biotinilated DR4/T*-1; DR/QNT-5; DR4/
QNT-Y peptide complexes were produced as described by
Parra-Lopez et al [39].
DR-ELISA, direct peptide-binding assays and calculation
of apparent Kd values
HLA DR4 peptide-binding studies were conducted using a
modification of an ELISA-based assay [37] that consists of 3 steps:
HLA-peptide complex formation, complex capture and complex
detection. In this assay, HLA-peptide complex formation was
achieved in 150 mL reactions containing different concentrations
(0 to 4 mM) of the biotin-labeled peptides: HA306–318; T*326–345;
T*-1327–338; QNT-5332–345; QNT-Y (L335Y) (in DMSO 10% final)
and 0.05 mM purified recombinant DR4 molecules in binding
buffer (100 mM citrate/phosphate buffer (pH 5.4), 0.15 mM
NaCl, 4 mM EDTA, 4% NP-40, 4 mM PMSF and 40 mg/mL)
for each of the following protease inhibitors: soybean trypsin
inhibitor, antipain, leupeptin and chymostatin, were incubated at
37uC. After 72 hours 50 mL samples of the reactions were
transferred (in duplicates) to BSA-blocked (Nunc-ELISA-Im-
muno-Modules Nunc-Maxisorp Loose Brand product, Denmark)
previously coated with 10 mg/mL of anti-HLA-DR mAb-LB 3.1
in PBS. After 2 hours of incubation at room temperature, plates
were washed with PBS, 0.05% Tween-20 and incubated for
1 hour with alkaline phosphatase-labeled streptavidin (Vector
Laboratories, Burlingame, California, USA). Captured biotin-
labeled peptide/DR4 complexes were revealed with 4-nitrophe-
nylphosphate substrate (Kirkegaard and Perry Laboratories,
Gaithersburg, Maryland, USA). For determining peptide binding
to HLA-DR molecules, a Titertek MC Multiscan ELISA reader
(Labsystems, Franklin, Massachusetts, USA) with 405 nm filter
was used. By measuring the optical densities (OD405 nm), the
amount of peptide bound was normalized with respect to the
maximum observed binding.
Peptide-binding competition assays
Peptide binding competition assays were conducted to measure
the ability of unlabeled peptides (T*, T*-1, T1, QNT-5, QNT-Y,
QNT-F, QNT-W; alanine peptide analogues and truncated
versions of QNT-5) to compete with the biotin-labeled indicator
peptide HA306–318 PKYVKQNTLKLAT for binding to DR4
molecules. Critical residues of QNT-5 for binding to DR4 were
defined by the use of a series of single substitution alanine QNT-5
analogues. For the competition assay unlabeled peptides at
concentrations ranging from 0 to 100 mM were mixed in binding
buffer together with biotin-labeled HA peptide (0.025 mM) and
DR4 molecules (0.05 mM) in a final 150 mL volume and the
reactions incubated for 72 hours at 37uC. Competition assays
were revealed using DR-ELISA described above, IC50 was
calculated by minimal squares and percentages of DR4 binding
inhibition were calculated by using the formula: 1006[1-
(DOD405 nm in the presence of competitor)/OD405 nm in the
absence of competitor peptide].
Assay of dissociation kinetics
Association reactions of DR4 with each of the biotin-labeled
peptides T*-1; QNT-5; QNT-Y and HA were performed by
incubation of 1 mM DR4 molecules with 10 mM biotin labeled
peptide in 400 mL binding buffer for 72 hours at 37uC. Biotin-
labeled peptides were removed from reactions by gel filtration
using Sephadex G50 columns. The reaction was then diluted 1:2
with binding buffer and split in two tubes (400 mL each). The
dissociation reactions in presence and absence of HLA-DM were
started by adding to one tube dissociation mix having 10 mM
unlabeled HA peptide and 1 mM HLA-DM and to the second
tube only 10 mM unlabeled HA peptide in a final volume of 2 mL.
At different time points, 200 mL aliquots of each dissociation
reaction (+/2 HLA-DM) were transferred into tubes having
20 mL of 1 M Tris pH 8.0 that were frozen immediately in
ethanol/dry ice and stored at 270uC until use. The thawed
dissociation mixtures were incubated in anti-DR1 Ab LB3.1
precoated 96-well Lumitrac 600 white plates (USA Scientific,
Ocala, FL, USA) at 4uC for 3 h, washed three times with PBS +
0.05% Tween-20, incubated with Europium-streptavidin at 37uC
for 1 hour, washed again, and then mixed with Europium
enhancement solution to release EU3+ (PerkinElmer, Shelton,
CT, USA). A Victor plate reader (PerkinElmer, Shelton, CT,
USA) was used to read the time-resolved fluorescence of EU3+.
The dissociation curve was fitted to single-phase exponential decay
with constraint 100% bound at time 0 in GraphPad Prism 5
(GraphPad software, San Diego, CA, USA) to determine the off
rate, koff, and half-life.
Molecular modeling
The X-ray crystal structures of a complex of a human alpha/
beta-TCR influenza HA antigen peptide and DR4 (PDB code
1J8H) [44] and DR4 with a peptide mimetic inhibitor of antigen
presentation by HLA-DR class II MHC molecules (PDB code
1D5Z) [45] were used as template for further modeling. The total
energy interaction of HA or peptide mimetic inhibitor with DR4
were determined first without including any further refinements
using docking software (Accelrys Software Inc., San Diego,
California, USA) run on an Indigo 2 Station (Silicon Graphics,
Sunnyvale, California, USA). In order to obtain the energetic
interaction of minimized peptide structures interacting with DR4,
the Discovery 3 program (Accelrys, San Diego, California, USA)
was used for simple minimization strategy using 20000 steps and
0.0001 A˚ RMSD. For modeling peptides QNT-Y and QNT-5
interacting with DR4, amino acids side chains of template peptides
were replaced by QNT-5 (LSTEWSPCS) and QNT-Y (YS-
TEWSPCS) side chains and the free energy of interaction of side
chains of amino acid residues of both peptides with corresponding
DR4 pockets (reported as explicit van der Waals (VDW) energy
Epitope Immunogenicity and MHC-Peptide Stability
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values) were determined with and without further refinements. To
analyze putative anchor residues at P1 in modeled peptides QNT-
5 and QNT-Y, the intermolecular energy of residues occupying P1
on template peptides HA and peptide mimetic inhibitor (Y and
cyclohexylalanine (Cha) respectively) was compared to those of L
and Y acting as P-1 anchoring residues of the QNT-5 peptide
sequence.
Immunization of DR4 transgenic mice
HLA-DR4 transgenic mice from Taconic Farms housed at the
University of Massachusetts in Worcester MA animal facility were
used in the experiments. Animals were handled and euthanized
according to University of Massachusetts Medical School Institu-
tional Animal Care and Use Committee approved through the
Animal Protocol A-1419. Three groups of four DR4 transgenic
mice (HLA-DRa1*01:01/DRb1*04:01) were immunized subcu-
taneously at the base of the tail with 50 mL of an emulsion
containing 50 mg of peptide T1B, T1BT* or T1BT*-Y in
Montanide ISA 720 as adjuvant or adjuvant alone as control.
Mice were immunized with two or three doses of the peptides or
adjuvant (20 days apart). One hundred to two hundred microliters
of blood was obtained from the facial vein of each experimental
mouse by a trained technician before each immunization.
Antibody titer determination
Anti-P. falciparum CS repeat immunoglobulin G (IgG) titers were
determined in individual serum samples by enzyme-linked
immunosorbent assay (ELISA) using immobilized (NANP)6
peptide, peroxidase-labeled species-specific anti-IgG antibody,
and 2,2-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) sub-
strate. Antibody titers were defined as the highest serum dilution
that yielded an ABTS optical density greater than the optical
density observed for the mean plus three standard deviations of
pre-immune serum. IgG subtypes were determined by ELISA
using biotin-labeled monoclonal antibodies to IgG1, IgG2a, IgG2b
and IgG3 (Biolengend) followed by peroxidase-labeled streptavidin
and ABTS. Each assay plate included positive control wells
covered with mouse IgG, IgG1, IgG2a, IgG3b or IgG3 (all from
BD Biosciences). A control monoclonal antibody (2A10) was used
Figure 1. Identification of residues in QNT-5 critical for binding to DR4. A series of QNT-5 analogues with single alanine substitutions (A)
and N- and C-terminal truncated QNT-5 peptides (B) were synthesized and tested at concentrations ranging from 0 to 100 mM for their ability to bind
to DR4. Relative binding was measured in a binding inhibition assay. The concentration of each alanine analogue or truncated peptide required to
reduce the binding of a biotin-labeled test peptide to 50% (IC50) is shown. The test peptide was a biotinylated version of HA (306PKYVKQNTLKLAT318),
a peptide from influenza hemagglutinin that binds strongly to DR4. Under the conditions used in this set of experiments, the IC50 for the HA peptide
was 0.3160.05 mM (Table S1). Representative findings from 3 experiments performed are shown (each point was performed in duplicate). Bars
represent SD.
doi:10.1371/journal.pone.0100639.g001
Epitope Immunogenicity and MHC-Peptide Stability
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also as a positive control for antibody responses to the P. falciparum
CS repeats [46].
Determination of IFN-c responses by ELISPOT in
splenocytes of DR4 transgenic mice immunized with
T1BT* or T1BT*-Y
IFN-c ELISPOT was performed using IFN-c ELISPOT Kit as
manufacturer instructions (eBiosciences, San Diego, CA, USA) in
PVDF plates (Millipore, Billerica, MA, USA). In brief, plates were
covered with 100 mL of capture antibody and after overnight
incubation at 4uC washed and blocked with RPMI-1640 +10%
FCS. Subsequently, 106 splenocytes in 100 mL of RPMI supple-
mented with 10% FCS were seeded per well and peptides (T*-1,
QNT-5, QNT-Y, HA) at a final concentration of 10 mg/mL
added. After 48 hours incubation at 37uC, 5% CO2 plates were
washed 3 times with 16 PBS, 0.05% Tween-20 and cytokine
revealed by successive incubation with detection antibody, wash,
peroxidase-HRP incubation, wash and final visualization with
AEC substrate. Plates were scanned and spots counted with the
help of an immunospot Analyzer (CTL-immunospot S6, Cellular
Technology Limited, USA).
Quantification of human CD4 T cells specific for T*-1;
QNT-5 and QNT-Y epitopes generated from naı¨ve CD4 T
cells primed in vitro with T1BT* and T1BT*-Y
Specific cell lines against T1BT* and T1BT*-Y peptide
constructs were generated from naı¨ve CD4 T cells from a HLA-
DRb1*04:01:01 donor using as APCs autologous monocyte
derived dendritic cells (DCs) as described by Moser and colleagues
[47]. CD4 T cells were purified using a naı¨ve CD4 T cell isolation
kit as manufacturer instructions (Miltenyi Biotec, Germany). DCs
were pulsed with 3.75 mM of peptides T1BT* or T1BT*-Y. DCs
were matured with TNF-a (25 ng/mL). Cells were co-cultured at
37uC, 5% CO2 for 14 days and re-stimulated at 1:10 ratio with
mature dendritic cells pulsed with 3.75 mM of the same peptide
used to prime. Seven days after the cells were stained with
fluorescent DR4/T*-1; DR4/QNT-5 and DR4/QNT-Y tetra-
mers assembled by stepwise addition of streptavidin-PE (Caltag,
Life technologies – California, USA) to biotinylated HLA-DR4–
peptide complexes at a final molar ratio of 1:4 as described [41]. T
cells were incubated with tetramers for 4 hours at 37uC followed
by 20 min incubation with cell surface markers: anti-CD3 PE-
Cy7, anti-CD4 PE-Texas red (Beckman Coulter, Palo Alto CA.
USA), anti-CD45RO FITC, anti-CD62-L PECy5 (all from BD
Biosciencies. San Diego CA. USA) on ice before washing with ice-
cold buffer. Tetramer and Ab binding were determined using an
FACS Aria II flow cytometer (BD Biosciences).
Statistical analysis
Raw ELISPOT data was analyzed by Kruskal-Wallis test with
Dunn’s Multiple Comparison Test to compare numbers of IFN-c
spot forming units (IFN-c SFU) between splenocytes of mice
immunized with peptide and control mice (vaccinated with
adjuvant only) upon stimulation in vitro with various assay
antigens (T1BT*, T1BT*-Y, T*-1; QNT-5, QNT-Y, T1 and
HA306–318). Anti-repeat antibody titers were analyzed with Mann
Whitney test.
Results
Identifying anchoring residues for QNT-5 binding to DR4
In a previous study we described two overlapping HLA-DR4-
binding epitopes within the universal CD4 T cell epitope T* from
T
a
b
le
1
.
A
m
in
o
ac
id
se
q
u
e
n
ce
o
f
T
*
an
d
D
R
4
e
p
it
o
p
e
s
u
se
d
in
th
is
st
u
d
y.
P
e
p
ti
d
e
A
m
in
o
a
ci
d
n
u
m
b
e
r
A
m
in
o
a
ci
d
se
q
u
e
n
ce
T
*
3
2
6
–
3
4
5
E
Y
L
N
K
I
Q
N
S
L
S
T
E
W
S
P
C
S
V
T
T
*-
1
3
2
7
–
3
3
8
Y
L
N
K
I
Q
N
S
L
S
T
E
Q
N
T
-5
3
3
2
–
3
4
5
Q
N
S
L
S
T
E
W
S
P
C
S
V
T
Q
N
T
-Y
3
3
2
–
3
4
5
Q
N
S
Y
S
T
E
W
S
P
C
S
V
T
H
A
3
0
6
–
3
1
8
P
K
Y
V
K
Q
N
T
L
K
L
A
T
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
0
6
3
9
.t
0
0
1
Epitope Immunogenicity and MHC-Peptide Stability
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e100639
P. falciparum [39]. MHC and T cell interactions were described for
T*-1, an epitope near the N-terminus of the T* peptide (CS327–338,
YLNKIQNSLSTE). A second epitope termed T*-5
(334SLSTEWSPCSV344) was mapped near the C-terminus of the
T* peptide, but was not fully characterized. Previous publications
that analyzed antigen-specific CD4 T cell clones isolated from
DR4 individuals vaccinated with a synthetic peptide vaccine
(T1BT*)4-Pam3Cys found that some of these clones recognized the
core SLSTEWSP sequence contained in T*-5 [36,38]. To perform
a fine mapping of the C-terminal epitope, and to analyze side-by-
side its HLA-DR4-binding interactions with those of T*, T*-1, and
control tight-binding viral peptide HA derived from influenza
heamaglutinin, we synthesized a series of peptide variants based on
QNT-5 (332QNSLSTEWSPCSVT345) (Table 1). The QNT-5
peptide corresponds to the T*-5 sequence elongated by two and
one residues at the N- and C- terminus of the core respectively.
We performed binding competition assays between biotin-labeled
HA and a set of unlabeled single alanine substitution analogues
and truncation variants of QNT-5. IC50 values for these peptides
are shown in Figure 1A and Table S1. Alanine substitution of L335
or S340 greatly decreased binding of QNT-5 (as indicated by high
IC50 values) with smaller effects observed upon substitution of E338
and P341. These effects are consistent with a binding frame in
which L335, E338, S340 and P341 of the QNT-5 peptide (black
Table 2. Interaction with HLA-DRb1*04:01 of HA and DR4 epitopes of T*.
Peptide Kd (nM) DM- Kd (nM) DM+ Half-life (min) Half-life DM (min) DM-sus (1023 min21 mM21) (c)
T* 248675.1 (a) 123.1561.05 ND ND ND
T*-1 42.61622.84 51.5969.30 3831 (b) 294 2.14
QNT-5 504.23686.23 714.163.90 304.8 105 4.33
HA 42.81639.93 44.77639.77 37200 5472.6 0.11
QNT-Y 25.47610.70 35.67620.50 8307 2589 0.18
a) Apparent equilibrium binding affinity.
b) Dissociation half-life from single exponential decay.
C)DM susceptibility. DM-sus was calculated by (koff,DM - koff,in)/[DM] as described by Yin et al., [4] where koff,in = ln2/Half-life, koff,DM = ln2/Half-life DM, and [DM] = 1 mM.
ND. Not done.
doi:10.1371/journal.pone.0100639.t002
Figure 2. Dissociation kinetics from DR4 of HA, T*-1 and QNT-5 peptides measured in presence and absence of HLA-DM. (A) Amino-
acid sequence and location of T*-1 and QNT-5 epitopes in T*. (B) Characterization of the dissociation behavior of peptide MHC complexes formed
after 72 h of complex formation. The curves shown represent single or double exponential decays that fit the data. Filled symbols represent the
decays values of the 3 DR4-peptide complexes in the presence of HLA-DM. Empty symbols represents the decay values of the complexes in the
absence of HLA-DM. A representative experiment from 2 experiments performed is shown (each time point was carried out in duplicate).
doi:10.1371/journal.pone.0100639.g002
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arrowheads in Figure 1A) bind in the canonical P1, P4, P6, and P7
pockets of HLA-DR4 [20,48,49]. As previously observed for other
[20,48–50] HLA-DR4-binding peptides alanine substitution at the
P9 position (S343) did not have a significant effect on QNT-5
binding (Figure 1A). Truncation analysis (Figure 1B) suggests that
peptides need to extend at least to the P(-1) position, since deletion
of S334 (QN335-343) significantly reduced binding to HLA-DR4,
even though the S334A substitution did not have a significant effect
(Figure 1A).
Apparent binding affinity (Kd) of peptide complexes in
presence and absence of HLA-DM
Previously we reported that T*-5 peptide bound to HLA-DR4
more weakly than the T*-1 peptide as evaluated by a competition
binding assay, with IC50 values of 0.9 and 0.2 mM, respectively
[39]. To evaluate the binding affinity more precisely and to
compare T*-1 and QNT-5 directly, we performed direct binding
assays using biotinylated variants of T*-1 and QNT-5 with a fixed
concentration of HLA-DR4 (see Methods). T*-1 bound more
tightly to HLA-DR4 than did QNT-5, with apparent Kd values of
tenfold lower, ,42 nM versus ,504 nM, respectively (Table 2
and Figure S1). Apparent Kd was similar in presence of HLA-DM
(,51 and,714 nM respectively), as expected since HLA-DM acts
as a peptide-exchange catalyst but does not alter the binding
equilibrium.
DR4/QNT-5 peptide complexes are highly unstable
We also evaluated the kinetic stability of purified DR4/T*-1
and DR4/QNT-5 complexes (Figure 2, Table 2). DR4/T*-1
formed a stable complex with half-life ,3800 min at 37uC,
although dissociation was still much quicker than for the
prototypical tight-binding viral peptide HA (half-life
37,000 min). DR4/QNT-5 formed a much less stable complex,
with half-life ,300 min. HLA-DM increased the dissociation of
both DR4/T*-1 and DR4/QNT-5 (half lives of ,300 and
,100 min respectively).
DR4/QNT-5 peptide complex instability can be reversed
by a tyrosine in QNT-5 occupying P1
Published results from Sant and others suggest that immuno-
dominance in CD4 T cell responses is primarily an intrinsic
property of peptide-class II complex stability that can be
modulated by manipulating MHC-peptide interactions [22]. The
unstable behavior DR4/QNT-5 led us to predict that it would be
poorly immunogenic and that this could be solved by the rational
modification of MHC-peptide complex stability. The T*-1
sequence is highly variable, with more than 28 variants reported
[51–55]; in contrast, QNT-5 (QNSLSTEWSPCSVT) is highly
conserved throughout several Plasmodium species and harbors a
sequence that overlaps with the region II sequence of the CS
protein (underlined) that is crucial for the entrance of sporozoites
into hepatocytes [56,57]. These attributes of QNT-5 and the fast
off rate of DR4/QNT-5 complexes even in absence of HLA-DM
(see Table 2) prompted us to focus our search on the structural
features of this sequence responsible for its unstable behavior using
a combination of computational and experimental approaches.
First, we analyzed the QNT-5 sequence using Propred [58], which
is a matrix-based algorithm that can be used for predicting peptide
binding to many MHC class II alleles, including the HLA-
DRb1*04:01 allele. Because this algorithm typically identifies
strong allele-specific preferences at positions P1, P4, P6 and P9,
based on docking data, we oriented the analysis to search for
amino acid substitutions at P1 that would improve binding of
QNT-5 to DR4. The results of these analyses predicted that the
QNT-5 peptide sequences with aromatic residues Y, F and W
substituted for L335 at P1 would enhance peptide binding (data not
shown). Second, a docking program for evaluating the probability
of MHC-peptide complex formation was used to determine the
explicit VDW energy value of the hydrophobic interactions at
each putative residue of the QNT-5 and QNT-Y (a QNT-5
analogue having L335Y substitution at P1) peptide sequences
occupying the P1, P4, P6 and P9 pockets at the peptide-binding
groove of DR4 (b1*04:01). After computational docking into a
MHC structure originally determined for a HA peptide complex
[44], significant differences between the QNT-5 and QNT-Y
peptides were observed only at the P1 pocket, as expected. The
free energy of this residue at P1, estimated by the VDW force
value for QNT-5 with the anchor residue L335 at P1, was 218.56
eV, which is substantially higher than that of Y318 with 242.06 eV
(Figure 3 and data not shown). The same analyses were performed
using a different MHC structural model consisting of a complex
with a peptidomimetic inhibitor that contains a cyclohexylalanine
side chain at P1 [45]. The same pattern was observed, with free
energies of 219.91 eV after minimization for L335 at P1 and
235.96 eV for Y318 (Figure 3 and data not shown). Thus, Y318 was
predicted to be more favorable in the P1 pocket than L335,
regardless of the starting model used for the calculations. This
information, together with the results of the algorithm prediction
of a peptide analogue of QNT-5 containing the L335Y substitution
at P1 (QNSYSTEWSPCSVT), hereafter named QNT-Y
(Figure 4A), which predicted a higher stability of Y over L335 at
P1 in DR4, led us to hypothesize that the DR4/QNT-Y peptide
complex might exhibit greater stability than the DR4/QNT-5
complex.
In order to evaluate experimentally whether a P1 substitution
could stabilize QNT-5 peptide, we performed competition binding
assays (IC50) for QNT-5, QNT-Y and the control tight-binding
HA peptide (Figure 4B). QNT-Y binds to DR4 with a relative
Figure 3. VDW energy value for the hydrophobic interactions
at P1 between DR4 and QNT-5 or an analogue of QNT-5 with a
L335Y substitution at P1 (peptide QNT-Y). VDW value after the
computational docking of peptides QNT-5 and QNT-Y into an MHC
(DRb1*04:01:01) structure, originally determined for the HA peptide and
peptidomimetic inhibitor complexes, with a tyrosine(a) [44] (left panel)
and a cyclohexylalanine(b) side chain at P1 [45] (right panel),
respectively. The height of the white- and dashed-boxes represents
the VDW free energy value expressed in eV for QNT-5 (L) with the
anchor residue L335 at P1 and for QNT-Y (Y) with Y318 at P1, respectively.
doi:10.1371/journal.pone.0100639.g003
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affinity ,10-20-fold higher than QNT-5 (IC50s ,130 nM vs.
,1700 nM) (range values 124.2–139.9 and 1528–1848 (95% C.I.)
respectively). The higher affinity of QNT-Y for DR4 was
evaluated also in a direct binding assay using biotinylated peptides,
in the presence and absence of HLA-DM. Compared to QNT-5,
the binding affinity of QNT-Y was increased ,20-fold with
apparent Kd values with and without HLA-DM of ,36 and
,25 nM, respectively (Table 2). Finally, having found that QNT-
Y exhibited a higher affinity for DR4, we sought to examine the
impact of the L335Y change at P1 on the kinetic stability of the
DR4/QNT-Y complex as well as the sensitivity of this peptide
complex to HLA-DM editing. We observed a ,25-fold increase in
the half-life of DR4/QNT-Y compared to DR4/QNT-5 com-
plexes in presence or absence of HLA-DM (lifetimes of ,2,500
and ,8,300 min, respectively (Figure 4C and Table 2)). These
results clearly demonstrate that the L335Y substitution at P1
reverses the unstable behavior of the DR4/QNT-5 peptide.
In DR4 transgenic mice a linear peptide malaria vaccine
candidate containing QNT-Y elicits higher anti-CS repeat
antibody titers than a peptide containing QNT-5 but the
effect is transient and long-term responses are reduced
The identification of QNT-5 variants with different kinetic
stabilities provides a useful system to analyze the role of epitope
stability in CD4 T cell immunodominance hierarchy and the
capacity to function as T helper epitopes in the anti-(NANP)3
antibody response. To determine the relative T helper activity of
QNT-5 and QNT-Y two peptides were synthesized, T1BT* and
T1BT*-Y (having the stable L335Y substitution in QNT-5
(Figure 5A)). Both peptides have in common the T1B sequence
that contains the minor T1 epitope [19,31] and three copies of the
NANP repeat that is the major antibody epitope in the P. falciparum
CS protein. Although T1 functions as a T cell epitope in DR4
haplotype malaria-immune individuals [19,31] we do not expect
significant T cell responses to T1 in DR4 transgenic mice
immunized with T1BT for two reasons: (i) in previous studies, a
DR4 individual immunized with a construct containing T1BT*
developed T cell response to T* but not to T1 [36,38] and (ii)
contrary to QNT-5 and QNT-Y (IC50 ,25 and ,500 respec-
tively, Table 2), T1 binds very weakly to DRb1*04:01 (IC50
,18000 nM, not shown). The ‘‘B’’ sequence functions as a
reporter for anti-CS repeat antibody responses, although ‘‘T1’’
sequences are also recognized. We used this construct because
previous studies demonstrated that T1BT* is highly immunogenic
in humans [36,38] and also because T1BT*-immunized mice are
protected when challenge with sporozoites in a murine malaria
model for P. falciparum [59].
Figure 4. Binding activity of QNT-Y and stability of the DR4/QNT-Y peptide complex. (A) Amino-acid sequence of QNT-5 and QNT-Y
peptide analogue. (B) Competition binding assay for QNT-5, QNT-Y and HA. The plots show the binding inhibition of the biotinylated HA306–318
peptide to DR4 using increasing amounts (0 to 20 mM) of unlabeled peptides to calculate the concentration of each peptide required to reduce the
binding of a biotin-labeled test peptide to 50% (IC50). Under the experimental conditions used here, the IC50 for the HA peptide was ,172 mM.
Representative results from 1 of 3 experiments performed are shown (each point was performed in duplicate). (C) Dissociation kinetics of the QNT-5
and QNT-Y peptides from DR4, measured in the presence (filled symbols) or absence (empty) of HLA-DM. A representative experiment of 3 performed
is shown (each time point was performed in duplicate). Bars represent SEM.
doi:10.1371/journal.pone.0100639.g004
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DR4 transgenic mice were immunized with T1BT* and
T1BT*-Y following a typical vaccination protocol, with three
immunization doses spaced 20 days apart collecting blood samples
before each immunization (days 0, 20, 40) and at days 67 and 85
after first dose (Figure 5B). Antibody titers throughout the
immunization scheme shown in figure 5B are summarized in
Figure 5C and Table 3. Figure 5C shows that 20 days after the first
dose, anti-(NANP)6 antibody titers in sera of mice immunized with
peptide T1BT*-Y (filled circles) were significantly higher (p,
0.001) than those detected in mice immunized with T1BT* (open
circles). However, anti-(NANP)6 antibody titers in sera of both
groups of animals were similar by the second dose, and antibody
titers in mice vaccinated with T1BT*-Y did not sustain in the long
term. Two months after the third dose the anti-(NANP)6 antibody
titers in mice vaccinated with T1BT*-Y were significantly lower
(p,0.05) than in mice vaccinated with T1BT* (Figure 5C). The
role of T* as a T helper epitope in the antibody response to
(NANP)6 elicited by immunization with T1BT* or T1BT*-Y was
corroborated by a lack of antibody responses in DR4 transgenic
mice immunized with T1B (Table 3). Using the same immuniza-
tion scheme shown in figure 5B, only one of four DR4 transgenic
mice immunized with a linear T1B peptide developed anti-
(NANP)6 antibody response, and this response was very weak with
titer 1:80 as compared to titers over 1:1000 in T1BT* and T1BT*-
Y immunized mice (Table 3). This led us to conclude that anti-
(NANP)6 antibody responses observed upon immunization of DR4
transgenic mice with T1BT* or T1BT*-Y are mostly associated
with help by T*.
Isotype specificity of the anti-repeat response elicited by
vaccination with T1BT* and T1BT*-Y
IgG isotype responses to T1BT* and T1BT*-Y in immunized
mice are presented in Figure 6. Mice immunized with these
constructs produce an early IgG1 response, with T1BT*-Y
inducing a stronger response. T1BT*-Y-immunized mice also
produced IgG2b and a low levels of IgG2a. Following a second
dose total IgG and IgG1 responses have similar strength in both
groups of mice, and IgG2b responses are now also observed in
T1BT* immunized mice (Figure 6B). Finally, after a third dose the
IgG2b antibody responses in T1BT*-Y are appreciable lower than
in T1BT* immunized mice (Figure 6C). Overall this pattern is
similar to that observed for the IgG titers reported in Figure 5C.
None of the constructs induced IgG3 responses to (NANP)6
peptide.
Peptides containing QNT-5 and QNT-Y epitopes elicit
IFN-c responses in DR4 transgenic mice
T cell responses elicited by T1BT* and T1BT*-Y were assessed
in splenocytes of DR4-transgenic mice using IFN-c as a readout.
IFN-c responses were measured in vitro after stimulation with
various assay antigens (T1BT*, T1BT*-Y, T*-1; QNT-5, QNT-Y,
Figure 5. Long term quantitation of anti-(NANP)6 Ab responses
by ELISA in mice vaccinated with T1BT* or T1BT*-Y peptides.
(A) Amino-acid sequences of T1BT* and T1BT*-Y polypeptides used for
vaccination of HLA-DR4 transgenic mice. T1BT* comprise T1 (a T cell
epitope from the 59minor repeat region of P. falciparum CS protein
[31]), B (three copies of immune-dominant B-cell repeat epitope (NANP)
from P. falciparum CS protein [97]) and the NF54 variant of T* epitope
that includes T*-1327 –338 YLNKIQNSLSTE and QNT-5332 –345
QNSLSTEWSPCSVT with L335 highlighted in red. T1BT*-Y is identical to
T1BT* except that QNT-5332–345 QNSYSTEWSPCSVT harbors the single
amino-acid substitution L335Y (in red). (B) Immunization scheme
indicating the days when serum samples were collected. (C) Anti-
(NANP)6 antibody titers in serum samples of mice immunized with
T1BT* (open) or T1BT*-Y (black circles) during the course of the
immunization protocol. The mean anti-(NANP)6 Ab titers correspond to
the average titer determined in the sera of groups of 3 DR4 transgenic
mice immunized with T1BT* or T1BT*-Y in 3 independent experiments.
(*) p,0.05; (**) p,0.001 Mann Whitney test, mean with SEM (standard
errors of the mean) bars are shown.
doi:10.1371/journal.pone.0100639.g005
Table 3. Anti-(NANP)6 antibody responses in DR4 transgenic mice after three subcutaneous immunizations with synthetic
peptides in Montanide ISA 720.
Immunogen Responders/Total GMT* Ab Titer Range#
T1BT* 4/4 17222 10240–40960
T1BT*-Y 4/4 1810 1280–2560
T1B 1/4 80 ,1:80–80
*Geometric Mean titers (GMT) and #Range of antibody titers in the group of mice immunized with peptides indicated in the first column.
doi:10.1371/journal.pone.0100639.t003
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T1 and HA306–318) and compared to splenocytes from mock-
immunized animals. The experimental protocol is shown in
figure 7A, and figure 7B summarizes the results observed after 2nd
dose (red symbols) and 3rd dose (gray symbols) immunization. In
general the observed responses were considerably weaker than
those previously reported in non-transgenic mice using a similar
immunization and assay strategy [59]. The responses in T1BT*
(diamonds) and T1BT*-Y (circles) immunized mice to their
respective immunogens were significantly higher than those in
control mice (squares, immunized with PBS/montanide). Weak
responses to QNT-5 and QNT-Y peptides were also observed.
IFN-c responses to T*-1, T1 and the control HA peptide were not
significantly higher than those in control mice for either
immunogen. Overall no significant difference in the IFN-c
response to any assay antigen was detected in comparisons of
mice immunized with T1BT* and T1BT*-Y.
IFN-c response to QNT-Y wanes over time and at forty-
five days after third dose is weaker than the response to
QNT-5
Antibody responses in T1BT*-Y were lower over time when
compared with T1BT* immunized mice (Figure 5C). To evaluate
if the IFN-c T cells response to QNT-5 and QNT-Y followed a
similar trend, splenocytes were obtained from mice immunized
with T1BT* and T1BT*Y 45 days after the third immunization
dose (Figure 7A) and their IFN-c response determined as above.
We found that similarly to antibody responses, IFN-c responses at
45 days to both QNT-5 and QNT-Y were significantly greater in
mice vaccinated with T1BT* as compared to T1BT*-Y
(Figure 7C). Moreover responses in T1BT*-Y mice were not
significant as compared to those in control mice. These results
suggest that QNT-5 is more effective than QNT-Y in inducing
long-term IFN-c T cells.
Human CD4 T cells primed in vitro with QNT-5 exhibit a
central memory phenotype and are cross reactive with
QNT-Y
Successful vaccination relies in the generation of long-term
memory T cells. The higher long-term Ab and IFN-c cellular
responses induced by the T1BT* construct as compared to
T1BT*-Y suggests that QNT-5 fosters the generation of central
memory T cells more efficiently than QNT-Y despite the
improved HLA-DR4 binding of QNT-Y. To investigate this in a
human setting, we looked at the ability of T1BT* and T1BT*-Y to
prime naı¨ve CD4 T cells ex vivo. DCs were pulsed with T1BT* or
T1BT*-Y and incubated together with naı¨ve CD4 T cells, and
three weeks later the cells were stained with anti-CD3, anti-CD4,
anti-CD62L, anti-CD45RO antibodies and with DR4 fluorescent
tetramers specific for T*-1; QNT-5 and QNT-Y (Figure 8A). The
use of fluorescent tetramers allowed us to compare the percentage
of CD4 T cells responding to each epitope as well as the
percentage of responding cells in memory and effector compart-
ments. DR4/QNT-5 and DR4/QNT-Y tetramer-positive cells
were detected in cultures that had been primed with either T1BT*
or T1BT*-Y (Figure 8B). T cells elicited against QNT-5 cross-
reacted with QNT-Y and vice versa (Figure 8B). The priming of
naı¨ve CD4 T cells with T1BT* led into a more vigorous expansion
of central memory CD4 T cells specific for QNT-5 than observed
for QNT-Y in cells primed with T1BT*-Y (14.9% vs. 4.51% of
TCM respectively in figure 8D and table 4). The percentages of
effector CD4 T cells specific for each epitope (TEF or TEM in
table 4), were not remarkably different between cultures primed
with either T1BT* or T1BT*-Y.
Discussion
In spite of significant advances in the understanding of the
biology of Plasmodium parasites and the immune response elicited
Figure 6. IgG Isotype responses in T1BT* and T1BT*-Y
immunized mice. IgG subtype of anti-(NANP)6 antibody responses
elicited in DR4 transgenic mice twenty days after the first (A), second (B)
and third dose (C) of T1BT* (white bars); T1BT*-Y (black bars) peptides
or Montanide ISA 720 (grey bars). The bars indicate mean delta O.D.
(optical density serum in wells coated with (NANP)6 minus PBS wells)
obtained with DR4 transgenic serum (1:80 dilution) incubated with
(NANP)6 peptide-coated ELISA plates and reacted with IgG subtype-
specific antibodies. Serum samples were tested individually and means
and standard deviation for the group are shown.
doi:10.1371/journal.pone.0100639.g006
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by these pathogens, there is not yet a subunit vaccine capable of
eliciting long lasting protection. Multiple studies have demon-
strated that antibodies to the repeat units in the CS protein can
neutralize Plasmodium sporozoites [13,60–63]. In humans, although
protected individuals have higher anti-repeat antibody titers than
non-protected individuals, the correlation between protection and
anti-CS antibody titers is not perfect (reviewed in [9,64]). A major
limitation for a P. falciparum vaccine based on antibody responses is
that the CS repeats region does not elicit T cell responses in most
individuals [18,19]. The search for CD4 T cell epitopes in the P.
falciparum CS protein has resulted in the identification of 4 T cell
epitopes in the C-terminal region of this protein designated as a
T*, Th2R, Th3R and CS.T3 [18,30,33]. T cell responses to
Th2R, Th3R and T* have also been reported in vaccines
immunized with the malaria vaccine RTS,S [35]. Genetic
variability in P. falciparum CS regions that harbor Th2R and
Th3R [18,55,65] is a major consideration in vaccines engineered
with these T helper epitopes [54,66,67]. However, it is not clear if
polymorphism is a consequence of immunological pressure
[55,68].
In this work we studied a highly conserved C-terminal epitope
from T* designated as QNT-5. Contrary to other major CD4 T
cell epitopes (T*-1, Th2R and Th3R) [18,30,39], QNT-5 spans a
highly conserved sequence and for this reason is a very attractive
Figure 7. Quantitation of IFN-c secreting cells in the spleens of mice after vaccination with T1BT* or T1BT*-Y by ELISPOT. (A)
Immunization scheme indicating the days when splenocytes for ELISPOT were collected. (B) The graph shows the mean number of splenocytes
producing IFN-c per 16106 cells from mice immunized with T1BT* (diamonds), T1BT*-Y (filled circles) or adjuvant/PBS (squares) after stimulation for
48 h in vitro with the assay antigens (T1BT*, T1BT*-Y, T*-1, QNT-5, QNT-Y, T1 and HA (10 mg/mL each)). The p values are relative to control mice
immunized with PBS/adjuvant; * p,0.05. Kruskal-Wallis test with Dunn’s Multiple Comparison Test. The IFN-c SFU at day 20 from mice immunized
with only 2 antigen doses is shown in red. Mean with SEM (standard error of the mean) bars are shown. (C) IFN-c secreting cells quantified by ELISPOT
at day 85 in spleens of DR4 transgenic mice immunized with T1BT* (open circles), T1BT*-Y (black) or adjuvant/PBS (gray) after stimulation for 48 h in
vitro with media (control) or the assay antigens HA; T*-1, QNT-5, QNT-Y (10 mg/mL each). (*) p,0.05; (**) p,0.001 Kruskal-Wallis test with Dunn’s
Multiple Comparison Test. Mean with SEM bars are shown.
doi:10.1371/journal.pone.0100639.g007
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epitope for subunit vaccine development. We identified a DR4-
binding register in QNT-5 characterized primarily by pocket 1
(L335) and pocket 6 (S340) anchor residues with smaller contribu-
tions from pocket 4 (E338) and pocket 7 (P341). Measurement of
different biophysical parameters of this MHCII-peptide interac-
tion revealed the highly unstable character of DR4/QNT-5
complex in the presence of HLA-DM. As a step toward the
development of a strategy for stabilizing this MHC-peptide
interaction in the presence of HLA-DM, we investigated the role
of the pocket 1 (P1) side chain, thought to be the major
determinant of HLA-DR binding. An MHCII-peptide complex
stable in the presence of HLA-DM was achieved after improving
the binding capacity of QNT-5 to HLA-DR4 by replacing the
naturally occupying L335 residue at P1 with the optimal P1 side
chain tyrosine. Previous studies of some peptide-based vaccines
have enhanced immunogenicity by improving MHC-peptide
interactions [69–71]. The in vitro peptide binding results reported
here suggested that this approach might potentially provide a
possible strategy to improve the immunogenicity of malaria
vaccine candidates based on T*. However, in vivo studies in DR4
transgenic animals indicated that any improvement in immuno-
genicity due to stabilizing the MHC-peptide interaction was
modest and transient, and the unstable parent QNT-5 epitope
elicited better long-term immune responses than the stable
modified QNT-Y.
Our in vitro peptide binding studies relied on inhibition of
binding of an indicator peptide to MHC DR4 molecules by
unlabeled competitor peptides, an assay commonly used to
evaluate MHCII-peptide interaction [72]. Although inhibition
assays can provide reliable rank measures of relative affinities, the
IC50 values are not necessarily linear with Kd values. Also, Kd
values refer to reactions at equilibrium, but the MHCII-peptide
interaction has several steps with very slow kinetics and
equilibrium is difficult or impossible to achieve. These reasons
led McConnell and colleagues [72,73] to propose that study of
complex kinetic stability with labeled peptides may be advanta-
geous over IC50 or Kd values. Moreover, abundant experimental
evidence indicates that MHCII-peptide complex stability is highly
influenced by HLA-DM molecules [25,74,75]. Thus we conducted
experiments to assess the stability of DR4/T*-1 and DR4/QNT-5
complexes in the presence and absence of HLA-DM. These
experiments showed that while the apparent Kd values of the two
peptide complexes were not remarkably affected by HLA-DM
(Table 2), the half-lives were significantly lower than those formed
by a control viral epitope (DR4/HA), and notably, that DR4/
QNT-5 complexes were highly unstable even in absence of HLA-
DM.
The issue of peptide editing by HLA-DM has stimulated
considerable research in identifying characteristics of class II-
peptide complex that can influence the complex susceptibility to
HLA-DM. Structural features, including peptide length [76],
destabilizing amino-acid residues [77,78], the rigidity of the P1
pocket of the class II molecules [79], and both anchor interactions
and hydrogen bonding [77,80–82] all have been shown to
influence class II-peptide complex susceptibility to HLA-DM. In
contrast with the limited availability until recently of structural
data on HLA-DM’s interaction with class II MHC proteins [83–
85], functional experimental data pointing out the important role
of anchor residues in conferring class II-peptide stability to HLA-
DM have been published [86,87]. Lazarski et al. and others show
that dissociation kinetics in live cells remarkably influence
immunogenicity of peptide-MHC complex in vivo [22,24,25] and
that replacing non-optimal residues at anchor positions is a
suitable way to gain resistance to HLA-DM and increase
immunogenicity in vivo. In their work, poorly immunogenic
epitopes can be converted to highly immunogenic epitopes in vivo
by optimizing peptide anchor residues such as P4 and P6 that
foster class II-peptide kinetic stability [25]. Similarly, Rinder-
knecht et al., observed increased HLA-DM resistance after
substitutions in the P4 and P6 pockets [88]. By optimizing the
P1 anchor residue we were able to convert DR4/QNT-5 into a
stable complex. This could be interpreted as the action of HLA-
DM in QNT-5 editing being oriented toward the P1 pocket as
proposed by others [77,82,85,89,90], but whether or not the
Figure 8. Human CD4 T cells specific for the QNT-5 epitope cross-react with QNT-Y and vice versa. (A) Prime-boost scheme used for the
in vitro priming of naı¨ve CD4 T cells with T1BT* or T1BT*-Y pulsed DCs from a DRb1*04:01:01 healthy individual. (B) Flow cytometric analysis of CD4
naı¨ve T cells following co-culture for 14 days with DCs pulsed with T1BT* (top) or T1BT*-Y (bottom) and re-stimulated with peptide-pulsed DCs for 6
days. Plots show the percentages of CD4 T cells stained with SA-PE QNT-5, with SA-PE QNT-Y tetramers or with SA-PE only among CD3+CD4+ T cells
after 21 days in culture. (C) CD4+ naı¨ve (TN) (CD45RO- CD62-L+), central memory (TCM) (CD45RO+ CD62-L+), effector (TEM) (CD45RO+ CD62-L-) and
terminal effector (TEMRA) (CD45RO- CD62-L-) T cell sub-populations were identified using flow cytometry by staining the cells after 21 days in culture
with fluorescently labeled anti-CD45RO and anti-CD62-L antibodies. The numbers in the plots correspond to the percentage of each sub-population
among CD3+CD4+ double-positive T cells. (D) Plots showing the percentages of CD4 T cells positive for QNT-5 and QNT-Y tetramers present among
the TN, TCM, TEM or TEMRA T cell sub-populations after 21 days in culture.
doi:10.1371/journal.pone.0100639.g008
Table 4. Percentage of tetramer positive CD4 T cells in different CD4 T cell sub-populations.
Cell line Tetramer % TN % TCM % TEF % TEM
T1BT* T*-1 0.76% 7.68% 0.87% 1.99%
QNT-5 0.00% 14.9% 1.1% 1.57%
QNT-Y 0.25% 7.3% 0.34% 0.84%
SA-PE 0.00% 0.06% 0.00% 0.00%
T1BT*-Y T*-1 0.00% 8.19% 0.79% 1.17%
QNT-5 0.18% 4.51% 1.94% 1.0%
QNT-Y 0.43% 4.34% 0.45% 0.78%
SA-PE 0.00% 0.06% 0.00% 0.00%
doi:10.1371/journal.pone.0100639.t004
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increased stability to HLA-DM of QNT-Y could be attributed to
synergistic effect on QNT-Y of anchor residues beyond P1 such as
P4, P6 and P7 as suggested by Lazarski et al [24,25] and
Rinderknecht et al [88] is a possibility that deserve further
investigation.
To assess the relative immunogenicity of the parent QNT-5 and
P1-optimized QNT-Y epitopes, DR4 transgenic mice were
immunized with linear peptides T1BT* or T1BT*-Y, and CD4
T cell IFN-c responses and anti-CS antibody responses were
studied. The T1BT* linear peptide was selected for these studies
because (i) this subunit vaccine candidate can be produced as a
synthetic linear peptide at low cost (ii) the T1BT* sequence has
already been used in clinical trials and shown to induce relative
high anti-sporozoite titers and T cell responses in individuals of
multiple MHC haplotypes [36,38] and (iii) in a P. berghei transgenic
model that expresses the P. falciparum repeats T1BT* has been
shown to elicit protective immune responses [59,91]. We expected
that the P1 substitution would increase the immunogenicity of
T1BT*-Y over T1BT*, as MHCII-peptide stability was dramat-
ically improved by this substitution (Figure 4). Surprisingly,
although short-term CD4 T cell and antibody responses in fact
were modestly improved by the substitution (Figure 7A and
Figure 5C) the improvement was short-lived, and by day 85, forty
five days after the last immunization dose, CD4 T cells responding
to QNT-Y were detected in numbers significantly lower compared
to cells specific for QNT-5 (Figure 7C). The effectiveness of QNT-
5 over QNT-Y in long term helper T cell function was also
indicated by high anti-(NANP)6 titers that lasted up to three
months in sera of mice vaccinated with QNT-5 not detected in
mice immunized with QNT-Y (Figure 5C). Similarly we observed
a higher capacity of DR4/QNT-5 over DR4/QNT-Y to prime
human naı¨ve CD4 T cells in vitro (Figure 8).
We performed an analysis of IgG isotype responses to the
(NANP)6 repeat peptide as a surrogate measure of the production
of Th2 associated cytokines that provide CD4 help to these
responses. Previous studies have reported that inbreed mice
immunized with T1BT* constructs have in their serum IgG
subtypes associated with both Th1 and Th2 cellular responses
[59,91]. We found that DR4 transgenic mice immunized with
T1BT*-Y initially have respectively stronger Th2–associated IgG1
and Th1-associated IgG2/b response than T1BT* immunized
mice. However, following a third dose, both IgG1 and IgG2/b are
more prominent in T1BT* immunized mice. The Th1-associated
IgG2a/b responses in T1BT*-Y mice show a dramatic decrease
over time (Figure 6), like the IFN-c responses observed for this
immunogen (Figure 7).
The poor immunogenicity of the stable DR4/QNT-Y com-
plexes is in contrast with previous studies from Sant and coworkers
where kinetic stability of MHC-peptide complexes correlates
directly with immunodominance during an immune response
[22,24,25], and with a recent study of Yin et al. [21], where DM-
mediated dissociation lifetime and DM-susceptibility values
correlated with human CD4 T cell response to peptides from
the major core protein A10L of vaccinia virus. The DM-
dependent half-life of DR4/QNT-5 was 105 min, three fold
lower than the lowest value of any T cell epitope found by Yin et al
(,370 min), indicating an unstable complex that predicts a limited
immunogenicity for CD4 T cells. The DM-mediated dissociation
lifetime was greatly improved by substitution of the P1 residue in
the DR4/QNT-Y complex, as was the intrinsic MHC-peptide
dissociation lifetime (Table 2). However, despite the instability of
the native DR4/QNT-5 complexes they were able to sustain a
long-term IFN-c responses and high anti-(NANP)6 antibody titers,
which were not substantially improved by increasing MHC-
peptide stability. These results do not fit with the expected
relationship between T cell immunogenicity and MHC-peptide
stability and particularly resistance to DM-mediated editing.
Why QNT-5 is more effective than QNT-Y in inducing long-
term T cell and antibody responses currently is not clear, but at
least two possibilities can be envisioned: First, the EWSPCSVTC
sequence in QNT-5 has a high degree of homology with
thrombospondin type-1 repeats (TSR-1) present in at least 41
human proteins [92,93], including thrombospondin-1, properdin
and F-spondin extracellular matrix proteins [94,95]. Alignment of
predicted DR4-binding epitopes from these self-proteins reveals
considerable similarity with QNT-5 and QNT-Y at MHC pocket
position P4 and P6 and potential T cell contact residues in position
5 and positions 8 to 12 (Table 5). Thus, T cells that prefer the C-
terminus region of T* might be modulated to avoid autoimmune
response, for example by Treg-based mechanisms, with the
improved stability of QNT-Y resulting in increased modulation.
Second, we are using a transgenic mouse model in which antigenic
peptides are presented by a hybrid mouse/DR4 molecule [96] that
might not have an optimal interaction with mouse DM molecule.
Taken together, our results indicate that the highly conserved
QNT-5 Th epitope of T* can be improved for interaction with
MHC DRb1*04:01 molecules and for resistance to HLA-DM
editing by inclusion of an optimal P1 residue, and that such
epitope engineering can transiently improve IFN-c and B cell
responses. However, the improvement in immunogenicity was
short-lived, and long-term immune responses were attenuated by
the modification. From our findings it is clear that additional
research is needed to understand the factors that govern immune
responses to T*.
Supporting Information
Figure S1 Direct peptide-binding assays and calculation
of apparent binding affinity (Kd). (A) Amino-acid sequence
Table 5. Homology of the P. falciparum CS protein sequence in QNT-5 (strain NF54) and selected self-proteins.
Protein Sequence ID Sequence
$
CS T* sp|P19597.2|CSP_PLAFO QNSLSTEWSPCSVTC
CS T*-Y ---Y-----------
Thrombospondin human gb|AAK34948.1|AF251058_1 PKW-AQ-----T---
Properdin gb|AAB63279.1| RW—WST-A------
VSGP/F-spondin dbj|BAB18461.1| LL-PWS---D----G
$
Underlined are MHC anchor residues in P1, P4, and P6; dashes indicate identical residues.
doi:10.1371/journal.pone.0100639.t005
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and location of T*-1 and QNT-5 epitopes in T*. (B) Plots showing
direct binding profile to DR4 of HA, T*, T*-1 and QNT-5 biotin
labeled peptides upon binding reactions set up with or without
1 mM of HLA-DM (closed and open symbols respectively). The
biotin labeled peptide/DR4 complexes carried out in duplicates
was revealed using DR-ELISA; the values plotted as fraction
bound are normalized respect to maximum binding achieved by
72 hours. The figure shows one representative experiment out of
three performed. Range of Kd values found in reactions performed
with and without HLA-DM are shown in table 2.
(TIF)
Table S1 Relative IC50 values of Alanine substitution
analogues and truncated versions of QNT-5.
(DOCX)
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